Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 03: 195 - 198

DOI: https://doi.org/10.16139/j.1007-9610.2021.03.003

Experts forum

Study on pathogenesis of cirrhotic portal hypertension: current status

Expand

Received date: 2021-04-19

  Online published: 2022-08-03

Fold

Cite this article

LUO Meng, LI Hongjie, ZHENG Lei . Study on pathogenesis of cirrhotic portal hypertension: current status[J]. Journal of Surgery Concepts & Practice, 2021 , 26(03) : 195 -198 . DOI: 10.16139/j.1007-9610.2021.03.003

References

[1] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):245-266.
[2] de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis[J]. Clin Liver Dis, 2001, 5(3):645-663.
[3] Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference[J]. Hepatology, 2008, 47(5):1764-1772.
[4] 郑磊, 孙隆慈, 罗蒙. 肝硬化患者门静脉压力及静脉曲张评估进展[J]. 肝胆胰外科杂志, 2016, 28(3):255-258.
[5] 罗蒙, 吴志勇. 门静脉压力测定在肝硬化门静脉高压症术式选择中的意义[J]. 外科理论与实践, 2009, 14(1):7-9.
[6] Lin J Y, Zhang CH, Zheng L, et al. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics(HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study[J]. BMJ Open, 2019, 9(12):e028518.
[7] Benoit JN, Womack WA, Hernandez L, et al. “Forward”and “backward” flow mechanisms of portal hypertension. relative contributions in the rat model of portal vein stenosis[J]. Gastroenterology, 1985, 89(5):1092-1096.
[8] Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl):S121-S130.
[9] Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol, 2011, 6:425-456.
[10] Herath CB, Mak K, Burrell LM, et al. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin Ⅱ and methoxamine via an endothelial nitric oxide-media-ted pathway in cirrhotic rat liver[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(1):99-108.
[11] Herath CB, Lubel JS, Jia Z, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 297(1):98-106.
[12] Fernandez M. Molecular pathophysiology of portal hypertension[J]. Hepatology, 2015, 61(4):1406-1415.
[13] Vorobioff JD, Groszmann RJ. Portal hypertension - molecular mechanisms[M]// Muriel P. Liver pathophysio-logy-therapies and antioxidants. United Kingdom: Academic Press, 2017:435-449.
[14] Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy[J]. Gastroenterology, 2000, 118(6):1261-1265.
[15] Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat[J]. Gastroenterology, 1999, 117(5):1222-1228.
[16] Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis[J]. Hepatology, 2006, 44(1):44-52.
[17] May D, Djonov V, Zamir G, et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations[J]. PLoS One, 2011, 6(7):e21478.
[18] Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdyna-mic state[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(5):G980-G987.
[19] Zhu Y, Ni T, Lin J, et al. Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS/NO signaling[J]. Biochimie, 2019, 163:128-136.
[20] Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis[J]. Gastroenterology, 2013, 145(4):874-884.
[21] di Pascoli M, Sacerdoti D, Pontisso P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2):92-99.
[22] Fernaandez M, Garciia-Pagaan JC, Casadevall M, et al. Acute and chronic cyclooxygenase blockage in portal-hyper-tensive rats: influence in nitric oxide biosynthesis[J]. Gastroenterology, 1996, 110(5):1529-1535.
[23] Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis[J]. Hepatology, 2005, 42(3):539-548.
[24] Adeagbo AS, Henzel MK. Calcium-dependent phospholipase A2 mediates the production of endothelium-derived hyperpolarizing factor in perfused rat mesenteric prearteriolar bed[J]. J Vasc Res, 1998, 35(1):27-35.
[25] Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule[J]. Hepatology, 2006, 43(2 Suppl 1):S121-S131.
[26] Du QH, Han L, Jiang JJ, et al. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats[J]. World J Gastroenterol, 2013, 19(13):2065-2072.
[27] Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins[J]. Hepatology, 2007, 45(2):495-506.
[28] Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease[J]. J Hepatol, 2009, 50(3):604-620.
[29] Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocolla-teral circulations in portal hypertensive and cirrhotic rats[J]. Hepatology, 2009, 49(4):1245-1256.
[30] Sumanovski LT, Battegay E, Stumm M, et al. Increased angiogenesis in portal hypertensive rats: role of nitric oxide[J]. Hepatology, 1999, 29(4):1044-1049.
[31] Angermayr B, Fernandez M, Mejias M, et al. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats[J]. Gut, 2007, 56(4):560-564.
Options
Outlines

/

〈 〉